Drug intelligence / Profile preview

MDC-301

Development stage: Preclinical
Lead developer: MediciBio
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

MDC-301 is a preclinical-stage vaccine candidate developed by MediciBio for the prevention of Highly Pathogenic Avian Influenza (HPAI), specifically targeting Clade 2.3.4.4.b H5N1 and other H5Nx variants. The vaccine utilizes MediciBio's proprietary capless self-amplifying mRNA (CLsaRNA) technology, which encodes influenza antigens and is delivered via lipid nanoparticles (LNPs). This approach is designed to elicit robust and protective immune responses against avian influenza strains that pose a significant pandemic threat to both poultry and public health.

Targets

HA (Hemagglutinin)

Beyond the preview

Go deeper on MDC-301.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MDC-301.

Explore the full profile